Tuberculosis and human immunodeficiency virus infection.

Area of Science:

• Infectious Diseases
• Immunology
• Public Health

Background:

• Human immunodeficiency virus (HIV) compromises host defenses, rendering individuals susceptible to opportunistic infections like tuberculosis (TB).
• Rising TB case rates are inferred, particularly among HIV-infected populations, highlighting a significant public health concern.
• Co-infection with HIV and Mycobacterium tuberculosis leads to substantially higher TB attack rates.

Purpose of the Study:

• To describe the epidemiology and clinical presentation of tuberculosis in patients with HIV infection.
• To outline recommended treatment and preventive strategies for TB in the context of HIV.
• To emphasize the importance of infection control and universal precautions in managing co-infected patients.

Main Methods:

• Review of inferential data on TB case rates in relation to HIV infection.
• Analysis of clinical features of TB based on the stage of HIV infection.
• Evaluation of treatment response and recommendations for preventive therapy.

Main Results:

• Tuberculosis often occurs earlier in HIV infection compared to other acquired immunodeficiency syndrome (AIDS)-defining illnesses due to Mycobacterium tuberculosis's high pathogenicity.
• Clinical presentations vary: atypical features (diffuse infiltration, no cavities, intrathoracic adenopathy, negative tuberculin skin tests) are common in late-stage HIV, while early stages resemble TB in HIV-seronegative individuals.
• Treatment response is generally favorable, with a recommended duration of at least 9 months.

Conclusions:

• Preventive isoniazid therapy is recommended for all HIV-seropositive individuals with a positive tuberculin skin test (≥5 mm).
• Tuberculosis must be considered in HIV-infected patients with pulmonary symptoms until ruled out.
• Healthcare providers should implement universal precautions due to the potential for co-existing, undiagnosed HIV infection in TB patients.